Core Viewpoint - Electrum Discovery Corp. has initiated a non-brokered private placement to raise up to approximately $1.4 million through the issuance of 20,000,000 units at a price of $0.07 per unit [1][3]. Group 1: Private Placement Details - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing the purchase of one common share at $0.15 for 24 months post-placement [2]. - The net proceeds from the offering will be allocated for exploration and development of mineral projects in Serbia, as well as for working capital and general corporate purposes [3]. - Certain insiders may participate in the private placement, and a finder's fee may be paid to registrants assisting in the placement [4]. Group 2: Regulatory and Compliance Information - The completion of the private placement is contingent upon receiving all necessary regulatory approvals, including from the TSX Venture Exchange [4]. - The securities issued will be subject to a four-month plus one day hold period under applicable Canadian securities laws [5]. Group 3: Company Overview - Electrum Discovery Corp. is a Canadian growth-oriented company focused on enhancing shareholder value through its two projects: gold-silver Novo Tlamino and copper-gold Timok East, located in Serbia's Western Tethyan Belt [6]. - The company aims to maximize the value of its mineral projects for stakeholders, including shareholders and the local community, while promoting sustainability and governance [7].

Core Points - Armory Mining Corp. has successfully closed the second and final tranche of its oversubscribed non-brokered private placement offering, raising a total of $853,000 [1][3] - The final tranche involved the issuance of 1,000,000 units at a price of $0.05 per unit, generating gross proceeds of $50,000 [2] - The funds raised will be utilized for working capital and general corporate purposes [3] Company Overview - Armory Mining is a Canadian exploration company focused on minerals critical to the energy, security, and defense sectors [4] - The company holds an 80% interest in the Candela II lithium brine project in Argentina and a 100% interest in the Riley Creek antimony-gold project in British Columbia [4] - Additionally, the company has an option to acquire a 100% interest in the Ammo antimony-gold project located in Nova Scotia [4]

Core Points - GAMMA Resources Ltd has successfully closed the first tranche of its private placement, raising gross proceeds of $651,060 [1] - The private placement consists of up to 8,333,334 units priced at $0.12 per unit, aiming for total gross proceeds of up to $1,000,000 [2] - Each unit includes one common share and one warrant, with warrants exercisable at $0.18 for 36 months [2][3] Financial Details - In the first tranche, the company issued 5,425,500 units at $0.12 each, with warrants expiring on September 5, 2028 [3] - Finders' fees amount to $13,650 in cash and 113,750 finders warrants, which have an exercise price of $0.12 for 24 months [3] Related Party Transactions - Directors of the company participated in the first tranche, acquiring a total of 417,000 shares, which is classified as a related party transaction [4] - The offering is exempt from formal valuation and minority shareholder approval requirements as it does not exceed 25% of the company's market capitalization [4] Securities Regulations - All securities from the private placement are subject to a four-month hold period and are not registered under U.S. securities laws [5] - The press release does not constitute an offer to sell or solicit offers to buy securities in the United States [5][9] Company Overview - GAMMA Resources Ltd focuses on uranium exploration and development in the U.S., with key projects in Utah and New Mexico [6] - The company aims to leverage favorable market conditions and policy changes in the U.S. nuclear sector to provide responsibly sourced uranium [6]

                                                                                                                                               Vancouver, B.C. September 5, 2025 – TheNewswire - Bathurst Metals Corp. (“Bathurst” or the “Company”) is pleased to announce it has entered into an Assignment and Assumption Agreement dated September 4, 2025 with an arm’s length vendors (the “Vendor”) to acquire an undivided 100% interest in one mineral claim comprising 81.6 hectares near Gold Bridge, B.C. known as ...

Core Viewpoint - Vanguard Mining Corp. has terminated its agreement with American Salars Lithium Inc. regarding the sale of the Pocitos 1 Lithium Salar Project, allowing the company to retain full ownership and exploration potential of the project [1][3]. Company Summary - The Pocitos 1 Lithium Salar Project is an 800-hectare lithium brine property located in Salta Province, Argentina, which is part of a prolific lithium brine district [1][6]. - The agreement with American Salars was initially announced on June 17, 2024, and included an inferred lithium carbonate equivalent (LCE) mineral resource estimate [2]. - The termination was due to American Salars' failure to meet local government payment obligations and other creditor responsibilities [3]. - Vanguard's President and CEO, David Greenway, emphasized that regaining control of Pocitos 1 protects shareholder interests and maintains exposure to a valuable lithium project [4]. Industry Summary - Lithium carbonate prices in China have recently rebounded to approximately CNY 78,720 per tonne (US$10,957/tonne), reflecting a more than 25% increase over the past month [5]. - The Pocitos 1 project is situated in a region that accounts for over 50% of the world's lithium brine resources, highlighting its global significance [6]. - Argentina has become a key player in the lithium market, with over US$14 billion invested by international companies in the past three years, driven by favorable geological conditions and supportive policies [12]. - The province of Salta is recognized as a favorable mining jurisdiction, attracting significant investment and project development [13][16]. - Global lithium demand is projected to triple by 2035, driven by the growth of electric vehicles and renewable energy systems [14].

 Toronto, Ontario – TheNewswire - 5 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announced today that it has elected not to proceed with the previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (together, “GEM”). The Company entered into a non-binding term sheet dated O ...

Brossard, Quebec – TheNewswire - September 5, 2025 – CHARBONE HYDROGEN CORPORATION (TSXV: CH; OTCQB: CHHYF; FSE: K47) (the “Company” or “CHARBONE”), a company focused on green hydrogen production and distribution, is pleased to announce it has signed, on September 4, 2025, an Asset Purchase Agreement to acquire operational hydrogen production and refuelling equipment in Quebec. The strategic acquisition will enable CHARBONE to fast-track the commissioning of CHARBONE’s flagship Sorel-Tracy facility phase 1 ...

Core Viewpoint - Allegiant Gold Ltd. has successfully closed a C$10.5 million private placement, primarily led by Kinross Gold Corporation, which increases Kinross's equity ownership in Allegiant to 9.9% on a partially diluted basis, enabling the company to advance its Eastside project over the next 2-3 years [1][4]. Financing Details - The Offering involved the issuance of 21,000,000 units at a price of C$0.50 per unit, with each unit comprising one common share and one-half of a common share purchase warrant [2]. - Each warrant allows the holder to acquire an additional common share at a price of C$0.70 for 18 months from issuance, with provisions for accelerated expiry if the share price exceeds CDN$1.00 for ten consecutive trading days [2][3]. Use of Proceeds - Proceeds from the Offering will fund Allegiant's multi-year development plan at the Eastside Project, including a comprehensive geophysics and mapping campaign, up to 20,000 meters of drilling, targeting new high-grade zones, and advancing towards future technical and economic milestones [6]. Financial Position - The financing positions Allegiant strongly for the next three years, with over $13 million in capital available to accelerate exploration and enhance resource quality [5][7]. - The 12-month hold period for securities issued reflects investor confidence and aims to create an equal footing for all investors, particularly U.S. investors [6]. Insider Participation - Certain insiders subscribed for a total of 97,300 units in the Offering, amounting to gross proceeds of $48,650, which is classified as a related party transaction [9]. Company Overview - Allegiant Gold owns three gold projects in Nevada, with the Eastside project being the flagship, hosting a large and expanding gold/silver resource [10].

TORONTO, Ontario – September 5, 2025 – TheNewswire - LAURION Mineral Exploration Inc. (TSXV: LME | OTCPINK: LMEFF) (“LAURION” or the “Corporation”) is pleased to provide this corporate update on its previously announced advisory engagements, exploration progress, and investor outreach initiatives. Reference is made to the Corporation’s press releases dated August 19, 2025, June 2, 2025, May 27, 2025 and May 8, 2025.  Advisory Network ExpansionAmid growing shareholder interest and evolving market access str ...

Company Overview - Universal Ibogaine Inc. (UI) is a life sciences company focused on transforming addiction treatment using medicalized ibogaine, specifically targeting opioid use disorder through a planned clinical trial in Canada [4] - The company is also developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, aimed at revolutionizing addiction treatment and improving the lives of affected individuals and families [4] Clinical Trial Announcement - UI intends to file a Clinical Trial Application (CTA) with Health Canada within 90 days to investigate ibogaine as a treatment for opioid use disorder [1] - The company has secured a reliable supply of pharmaceutical-grade ibogaine, produced in compliance with Good Manufacturing Practice (GMP) standards, ensuring quality and safety for the clinical trial [2] Leadership Statement - CEO Nick Karos emphasized the company's commitment to advancing innovative addiction therapies and expressed confidence in conducting rigorous clinical studies focused on patient safety and therapeutic effectiveness [3]